title: Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.
abstract: Multiple cholesterol-reducing therapies have been shown to induce the regression of tendon xanthoma in patients with familial hypercholesterolemia. We present 3 cases of adverse reactions in Achilles tendon xanthomas after the addition of niacin and bile acid sequestrants to ongoing statin therapy. Reduction in tendon dimensions and marked softening of xanthomas were interpreted as cholesterol removal from heavily infiltrated tissue sites. In 2 cases, changes in the xanthomas occurred despite only minor lipoprotein improvements, raising the possibility of direct drug effects in cholesterol-infiltrated tissue. Intriguingly, recent studies have described niacin receptor-mediated effects in macrophages. In summary, although adverse reactions in Achilles tendon xanthomas appear to be infrequent, clinicians should be aware of this phenomenon in their patients after intensifying lipid treatments, especially with the use of niacin in patients with familial hypercholesterolemia. Xanthoma responses may provide clues to new pharmacologic effects in cholesterol-infiltrated tissues.
authors: Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. lakey001@mc.duke.edu
authors: Wanda C
authors: WC
authors: Lakey
authors: Nicole
authors: N
authors: Greyshock
authors: John R
authors: JR
authors: Guyton
mesh_terms: D000125:Achilles Tendon; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004359:Drug Therapy, Combination; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000009:adverse effects* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy; D014973:Xanthomatosis / Q000175:diagnosis* / Q000209:etiology / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D001647:Bile Acids and Salts; D000960:Hypolipidemic Agents; D009525:Niacin